APRE Aprea Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: APRE

Price (delayed)

$3.95

Market cap

$21.45M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.32

Enterprise value

-$10.96M

Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor ...

Highlights
The quick ratio has soared by 121% from the previous quarter and by 49% YoY
APRE's EPS has surged by 96% year-on-year and by 16% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.aprea.com
Peers: HCSG ADUS AMED

Key stats

What are the main financial stats of APRE
Market
Shares outstanding
5.43M
Market cap
$21.45M
Enterprise value
-$10.96M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.74
Price to sales (P/S)
17.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-11.37
Earnings
Revenue
$963,800
EBIT
-$13.97M
EBITDA
-$13.96M
Free cash flow
-$13.15M
Per share
EPS
-$3.32
Free cash flow per share
-$3.13
Book value per share
$5.33
Revenue per share
$0.23
TBVPS
$7.91
Balance sheet
Total assets
$33.2M
Total liabilities
$4.28M
Debt
$0
Equity
$28.92M
Working capital
$30.1M
Liquidity
Debt to equity
0
Current ratio
11.15
Quick ratio
10.93
Net debt/EBITDA
2.32
Margins
EBITDA margin
-1,447.9%
Gross margin
100%
Net margin
-1,319.5%
Operating margin
-1,452.5%
Efficiency
Return on assets
-46.1%
Return on equity
-56.8%
Return on invested capital
N/A
Return on capital employed
-46.2%
Return on sales
-1,449.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

APRE stock price

How has the Aprea Therapeutics stock price performed over time
Intraday
3.67%
1 week
3.4%
1 month
-1.99%
1 year
31.67%
YTD
-15.96%
QTD
-2.95%

Financial performance

How have Aprea Therapeutics's revenue and profit performed over time
Revenue
$963,800
Gross profit
$963,800
Operating income
-$14M
Net income
-$12.72M
Gross margin
100%
Net margin
-1,319.5%
Aprea Therapeutics's net income has surged by 88% YoY and by 11% QoQ
Aprea Therapeutics's operating income has soared by 87% YoY and by 10% from the previous quarter
The company's gross profit has surged by 65% QoQ
Aprea Therapeutics's revenue has soared by 65% from the previous quarter

Growth

What is Aprea Therapeutics's growth rate over time

Valuation

What is Aprea Therapeutics stock price valuation
P/E
N/A
P/B
0.74
P/S
17.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-11.37
APRE's EPS has surged by 96% year-on-year and by 16% since the previous quarter
APRE's P/B is 71% below its 5-year quarterly average of 2.5 and 20% below its last 4 quarters average of 0.9
The equity has soared by 71% from the previous quarter and by 9% YoY
Aprea Therapeutics's revenue has soared by 65% from the previous quarter
APRE's P/S is 50% below its last 4 quarters average of 33.2

Efficiency

How efficient is Aprea Therapeutics business performance
The company's return on equity has surged by 94% YoY and by 13% QoQ
Aprea Therapeutics's ROA has soared by 86% YoY and by 12% from the previous quarter
APRE's return on sales is up by 46% since the previous quarter

Dividends

What is APRE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for APRE.

Financial health

How did Aprea Therapeutics financials performed over time
The quick ratio has soared by 121% from the previous quarter and by 49% YoY
The current ratio has soared by 117% from the previous quarter and by 47% YoY
The debt is 100% smaller than the equity
The equity has soared by 71% from the previous quarter and by 9% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.